

Chloe J Jordan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3278097/publications.pdf>

Version: 2024-02-01

53
papers

1,445
citations

394421

19
h-index

361022

35
g-index

58
all docs

58
docs citations

58
times ranked

1679
citing authors

#	ARTICLE	IF	CITATIONS
1	Involvement of the ghrelin system in the maintenance of oxycodone self-administration: converging evidence from endocrine, pharmacologic and transgenic approaches. <i>Molecular Psychiatry</i> , 2022, 27, 2171-2181.	7.9	9
2	Neuropsychopharmacology (NPP) 2020 report on gender balance among corresponding authors and reviewers: before and during the COVID-19 pandemic. <i>Neuropsychopharmacology</i> , 2022, 47, 973-975.	5.4	3
3	Effects of the COVID-19 pandemic on gender representation among corresponding authors of Neuropsychopharmacology (NPP) manuscripts: submissions during January–June, 2020. <i>Neuropsychopharmacology</i> , 2021, 46, 269-270.	5.4	7
4	Definitions of neonatal abstinence syndrome in clinical studies of mothers and infants: an expert literature review. <i>Journal of Perinatology</i> , 2021, 41, 1364-1371.	2.0	14
5	New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 609-628.	9.4	36
6	Optogenetic brain stimulation reward: A new procedure to reevaluate the rewarding <i>versus</i> aversive effects of cannabinoids in dopamine transporter–Cre mice. <i>Addiction Biology</i> , 2021, 26, e13005.	2.6	19
7	Neuropsychopharmacology (NPP): update on relationships between online attention and citation counts. <i>Neuropsychopharmacology</i> , 2021, 46, 1061-1063.	5.4	1
8	Pharmacology in the age of circuit neuroscience: Illuminating the neural mechanisms of reward, drug use and addiction and enlightening the future of translational research. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 206, 173187.	2.9	0
9	Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Part II: The clinical application of nonpharmacologic care for NAS/NOWS. <i>Neurotoxicology and Teratology</i> , 2021, 88, 107032.	2.4	12
10	Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. <i>Neurotoxicology and Teratology</i> , 2021, 88, 107020.	2.4	5
11	Synaptic Zn ²⁺ potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior. <i>Translational Psychiatry</i> , 2021, 11, 570.	4.8	3
12	Perinatal Substance Use Disorders: Intrauterine Exposure. , 2021, , 1529-1547.		0
13	Identification of the Risk Genes Associated With Vulnerability to Addiction: Major Findings From Transgenic Animals. <i>Frontiers in Neuroscience</i> , 2021, 15, 811192.	2.8	6
14	Dopamine, behavior, and addiction. <i>Journal of Biomedical Science</i> , 2021, 28, 83.	7.0	25
15	Dissecting the Role of GABA Neurons in the VTA<i>versus</i>SNr in Opioid Reward. <i>Journal of Neuroscience</i> , 2020, 40, 8853-8869.	3.6	61
16	Virtual meetings: A critical step to address climate change. <i>Science Advances</i> , 2020, 6, .	10.3	8
17	Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents. <i>Neuropharmacology</i> , 2020, 176, 108241.	4.1	13
18	Introduction to the Special Issue on “Informing Longitudinal Studies on the Effects of Maternal Stress and Substance Use on Child Development: Planning for the HEALTHY Brain and Child Development (HBCD) Study” Adversity and Resilience Science, 2020, 1, 217-221.	2.6	16

#	ARTICLE	IF	CITATIONS
19	(\pm)VK4-40, a novel dopamine D ₃ receptor partial agonist, attenuates cocaine reward and relapse in rodents. <i>British Journal of Pharmacology</i> , 2020, 177, 4796-4807.	5.4	15
20	ACNP efforts toward reducing climate change. <i>Neuropsychopharmacology</i> , 2020, 45, 2137-2138.	5.4	0
21	Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions. <i>Neuropsychopharmacology</i> , 2020, 45, 1518-1526.	5.4	13
22	Gap Junctions Modulate The Effects Of Modafinil On Cocaine Self-Administration Behavior In A Dopamine-Independent Fashion In Rats. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
23	CB2 receptor antibody signal specificity: correlations with the use of partial CB2-knockout mice and anti-rat CB2 receptor antibodies. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 398-409.	6.1	42
24	Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 365-373.	6.1	37
25	Neuropsychopharmacology (NPP): relationships between online attention and citation counts. <i>Neuropsychopharmacology</i> , 2019, 44, 1513-1515.	5.4	5
26	NPP (Neuropsychopharmacology): update on gender balance in journal function. <i>Neuropsychopharmacology</i> , 2019, 44, 2145-2148.	5.4	4
27	Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine. <i>Neuropharmacology</i> , 2019, 158, 107609.	4.1	44
28	Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders. <i>Neuropsychopharmacology</i> , 2019, 44, 1435-1444.	5.4	35
29	The highly selective dopamine D ₃ antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. <i>Neuropharmacology</i> , 2019, 158, 107597.	4.1	51
30	Newly Developed Dopamine D ₃ Receptor Antagonists, R-VK4-40 and R-VK4-116, Do Not Potentiate Cardiovascular Effects of Cocaine or Oxycodone in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 602-614.	2.5	24
31	Juvenile exposure to methylphenidate and guanfacine in rats: effects on early delay discounting and later cocaine-taking behavior. <i>Psychopharmacology</i> , 2019, 236, 685-698.	3.1	13
32	Neuropsychopharmacology (NPP): gender balance in journal function. <i>Neuropsychopharmacology</i> , 2019, 44, 4-8.	5.4	8
33	Progress in brain cannabinoid CB2 receptor research: From genes to behavior. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 98, 208-220.	6.1	139
34	Cannabis Use Disorder During the Perinatal Period. , 2019, , 177-188.		2
35	mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism. <i>Scientific Reports</i> , 2018, 8, 3686.	3.3	32
36	Discovery and development of varenicline for smoking cessation. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 671-683.	5.0	65

#	ARTICLE	IF	CITATIONS
37	Working memory and salivary brain-derived neurotrophic factor as developmental predictors of cocaine seeking in male and female rats. <i>Addiction Biology</i> , 2018, 23, 868-879.	2.6	11
38	Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats. <i>Neuropsychopharmacology</i> , 2018, 43, 2615-2626.	5.4	18
39	Perinatal Marijuana Use and the Developing Child. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 545.	7.4	38
40	Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice. <i>Neuropharmacology</i> , 2018, 141, 11-20.	4.1	20
41	Sensitive periods of substance abuse: Early risk for the transition to dependence. <i>Developmental Cognitive Neuroscience</i> , 2017, 25, 29-44.	4.0	246
42	Attention Deficit Hyperactivity Disorder (ADHD): Methylphenidate (Ritalin) and Dopamine. , ,		0
43	Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood. <i>Psychopharmacology</i> , 2016, 233, 3891-3903.	3.1	16
44	Adolescent d-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood. <i>Behavioural Brain Research</i> , 2016, 297, 165-179.	2.2	20
45	Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments. <i>Drug and Alcohol Dependence</i> , 2014, 140, 25-32.	3.2	36
46	Performance on a strategy set shifting task in rats following adult or adolescent cocaine exposure. <i>Psychopharmacology</i> , 2014, 231, 4489-4501.	3.1	19
47	Systemizing and special interests: Characterizing the continuum from neurotypical to autism spectrum disorder. <i>Learning and Individual Differences</i> , 2014, 29, 98-105.	2.7	38
48	Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: Methylphenidate vs. atomoxetine treatments. <i>Behavioural Brain Research</i> , 2013, 244, 38-47.	2.2	31
49	Adolescent Atomoxetine Treatment in a Rodent Model of ADHD: Effects on Cocaine Self-Administration and Dopamine Transporters in Frontostriatal Regions. <i>Neuropsychopharmacology</i> , 2013, 38, 2588-2597.	5.4	37
50	Neural regulation of the time course for cocaine cue extinction consolidation in rats. <i>European Journal of Neuroscience</i> , 2013, 37, 269-277.	2.6	13
51	C.10 - METHYLPHENIDATE AND ATOMOXETINE TREATMENT IN THE SPONTANEOUSLY HYPERTENSIVE RAT MODEL OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER. <i>Behavioural Pharmacology</i> , 2013, 24, e33.	1.7	0
52	Understanding Differences in Neurotypical and Autism Spectrum Special Interests Through Internet Forums. <i>Intellectual and Developmental Disabilities</i> , 2012, 50, 391-402.	1.1	68
53	Evolution of Autism Support and Understanding Via the World Wide Web. <i>Intellectual and Developmental Disabilities</i> , 2010, 48, 220-227.	1.1	66